![](https://endpts.com/wp-content/uploads/2021/08/Scott-Wolchko-Fate-tile-scaled.jpg)
Scott Wolchko, Fate Therapeutics CEO
Fate's closely watched stem cell-derived NK program raises red flag over durability of response
At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.